Ehsan Rahimy, MD

Ehsan Rahimy, MD; David G. Miller, MD; and Michael Klufas, MD, discuss how real-world treatment strategies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.

Ehsan Rahimy, MD; David G. Miller, MD; and Michael Klufas, MD, discuss how real-world treatment strategies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.

Ehsan Rahimy, MD; David G. Miller, MD; and Esther Kim, MD, discuss how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases such as AMD and DME, while highlighting the benefits of newer agents such as aflibercept 8 mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.

Ehsan Rahimy, MD; David G. Miller, MD; and Esther Kim, MD, discuss how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases such as AMD and DME, while highlighting the benefits of newer agents such as aflibercept 8 mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.

Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.

Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.

Ehsan Rahimy, MD, outlines strategies for managing cases of high-risk PDR and DME, exploring new therapies and synergistic combinations with anti-VEGF and steroids for longer-lasting responses.

An expert retina specialist discusses challenges faced by DME patients showing suboptimal response to standard anti-VEGF treatment, emphasizing the need to reduce injection burden while preventing vision loss.

Ehsan Rahimy, MD, discusses challenges in managing longstanding nAMD patients rotating through anti-VEGF treatments, highlighting the promise of newer therapies like aflibercept 8mg and faricimab.

Retina expert shares his strategy for managing a patient recently diagnosed with nAMD who started on bevacizumab, discussing criteria for transitioning to more efficacious therapy.

Ehsan Rahimy, MD addresses barriers like step edits with bevacizumab and biosimilars in nAMD, emphasizing the impact of insurance-guided choices on treatment outcomes and advocating for a personalized approach.

Experts wrap up their discussion by highlighting key takeaways on the treatment of retinal diseases with anti-vascular endothelial growth factor (Anti-VEGF) therapies.

Experts discuss emerging gene therapies for age-related macular degeneration (AMD) or diabetic macular edema (DME) and key end points considerations.

Experts discuss prospective therapies for age-related macular degeneration (AMD) or diabetic macular edema (DME) treatment.

Experts discuss the recent PULSAR and PHOTON studies with high dose aflibercept (8mg) and how they educate patients about this treatment approach.

Experts discuss clinical trials on the efficacy of faricimab and how they utilize this therapy in their practice.

Experts discuss insurer mandated step therapy and how to navigate treatment options for patients with diabetic macular edema (DME).

Experts discuss the recent DRCR Protocol AC study comparing aflibercept monotherapy vs bevacizumab first therapy for patients with diabetic macular edema (DME).

Experts discuss the results of Protocol T study comparing anti-vascular endothelial growth factor (Anti-VEGF) agents for the treatment of diabetic macular edema (DME).

Experts discusses the unique challenges managing the care of patients with diabetic macular edema (DME).

Experts discuss prospective therapies and improved outcome targets for patients with neovascular age-related macular degeneration (nAMD).

Experts discuss their experience using the treat and extend strategy with aflibercept and their clinical advice when administering treatment.

Experts discuss the long-term efficacy and safety of aflibercept in the treatment of neovascular age-related macular degeneration (nAMD).

Experts discuss the comparison of age-related macular degeneration treatments trials (CATT) and how today’s retina specialists can apply the results in their daily practice.

Experts discuss how they define suboptimal responders to anti-vascular endothelial growth factor (Anti-VEGF) treatment and how they manage the care of those patients.

Experts offer clinical advice on identifying and managing suboptimal responders on anti-vascular endothelial growth factor (Anti-VEGF) treatment.

Experts discuss the management of subretinal fluid (SRF) and intraretinal fluid (IRF) in patients with neovascular age-related macular degeneration (nAMD).

Veeral Sheth, MD, MBA, FASRS, FACS, offers clinical advice on marking disease progression in neovascular age-related macular degeneration (nAMD).

Experts offer their clinical experience and advice for applying a treat and extend strategy with anti-vascular endothelial growth factor (Anti-VEGF) injections.

Experts discuss safety data of anti-vascular endothelial growth factor (Anti-VEGF) agents while highlighting the importance of sharing this information with patients and relevant care providers.